Filing Details

Accession Number:
0001104659-22-049930
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-26 06:48:12
Reporting Period:
2022-04-22
Accepted Time:
2022-04-26 06:48:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1635088 Roivant Sciences Ltd. ROIV Pharmaceutical Preparations (2834) 981173944
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1636684 Ltd. Holdings Dexxon 1 Dexcel Street
Or Akiva L3 3060000
No No Yes No
1636701 Dan Oren 1 Dexcel Street
Or Akiva L3 3060000
No No Yes No
1720007 Ltd. Technologies Pharma Dexcel 21 Nahum Haftzadi Street
Jerusalem L3 9548402
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2022-04-22 31,685 $3.83 98,840,843 No 4 P Direct
Common Shares Acquisiton 2022-04-25 8,600 $3.91 98,849,443 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
  2. The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.
  3. The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.
  4. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.